Physicians may be on the road to a polypharmacy crisis in the development of new drugs for heart failure. They must somehow learn how to tailor the therapy to individual patients, rather than treating all patients with every potentially beneficial drug. This will not be an easy task, 3a but the current model of rational drug development followed by a large megatrial is costly and not likely to be sustained indefinitely.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Nov 17 2001|